BioSpace News Archive

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth.

PPD is part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and its PPD clinical research business are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines.

Dimension Therapeutics was acquired by Ultragenyx in 2017.

Biopact is a Molecular Rebar Design Company focusing on nanoscale biomaterials company developing the MGMR intracellular delivery vehicle. MGMR is a cellular-engineering tool for biomanufacturing and agricultural processes which value efficient delivery of RNAs, peptides, and genetic materials.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases.

Merck & Co. has acquired Calporta.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers.

Inozyme Pharma was acquired by BioMarin Pharmaceuticals in July 2025.